SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report: December 23, 1997 Commission file number: 0-24930
CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT, INC.
(Exact name of registrant as specified in its charter)
FLORIDA 59-3029743
(State or other jurisdiction (IRS Employer
of incorporation or organization) Identification No.)
3713 SW 42nd Avenue, Suite 3, Gainesville, Florida, 32608-6581
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 352-375-6822
<PAGE>
Item 4 - Changes in Registrant's Certifying Accountant
(a) On December 23, 1997, Registrant engaged the accounting firm of James Moore
& Co., C.P.A., as independent accountants for the Registrant for 1997. The
work of Davis, Monk & Co., C.P.A., was terminated on December 23, 1997. The
termination of Davis, Monk & Co. and the engagement of James Moore & Co. was
approved by Registrant's Board of Directors.
(b) During the period of engagement of Davis, Monk & Co., which has been since
December 5, 1996, there have been no disagreements between them and Registrant
on any matter of accounting principles or practices, financial statement
disclosure, auditing scope or procedure, or reportable events.
(c) Davis, Monk & Co.'s reports on the financial statements for its period of
engagement by Registrant contained no adverse opinion or disclaimer of opinion
and was not qualified or modified as to uncertainty, audit scope or accounting
principles.
(d) The Registrant requested that Davis, Monk & Co. furnish it with a
letter addressed to the Securities and Exchange Commission stating whether or
not it agrees with the statements made by the Registrant in response to this
Item 4 and if not, stating the respects in which it does not agree. Registrant
delivered a copy of this Form 8-K Report to Davis, Monk & Co. on December 23,
1997. By letter dated December 26, 1997, Davis, Monk & Co. stated that it
agreed with the information contained in this report on Form 8-K. The
Registrant herewith files a copy of such letter as an exhibit to this report
<PAGE>
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K
Exhibit Description Page
(1) Underwriting agreement None
(2) Plan of acquisition, reorganization,
arrangement, liquidation or succession None
(4) Instruments defining the rights of
security holders, including debentures None
(16) Letter re change in certifying accountant 5
(17) Letter re director resignation None
(21) Other documents or statements to security holders None
(24) Consents of experts and counsel None
(25) Power of attorney None
(28) Additional exhibits None
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CYCLODEXTRIN TECHNOLOGIES
DEVELOPMENT, INC.
(Registrant)
DATED: December 23, 1997
By: _________/S/__________________________
C. E. RICK STRATTAN, President, Chief
Executive Officer, and Chief Financial
Officer
[DAVIS MONK & COMPANY LETTERHEAD]
December 26, 1997
Mr. C.E. "Rick" Strattan
Cyclodextrin Technologies Development, Inc.
3713 S.W. 42 Avenue, Suite 3
Gainesville, Florida 32608-6518
Dear Mr. Strattan:
We have reviewed the form 8-K provided to us on December 23, 1997 and
agree with the information contained therein.
/S/ Davis, Monk & Company
DAVIS, MONK & COMPANY
CERTIFIED PUBLIC ACCOUNTANTS
& BUSINESS CONSULTANTS
HLM:wfb
